Clinicopathologic change of gastrointestinal stromal tumor after neoadjuvant imatinib followed by surgical resection.
10.4174/jkss.2012.82.2.120
- Author:
Gil Ho KANG
1
;
Myoung Won SON
;
Sun Wook HAN
;
Sang Ho BAE
;
Sung Yong KIM
;
Yong Jin KIM
;
Gui Ae CHUNG
;
Gyu Seok CHO
;
Moon Soo LEE
;
Nae Kyeong PARK
Author Information
1. Department of Surgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
- Publication Type:Case Report
- Keywords:
Gastrointestinal stromal tumors;
Imatinib;
Neoadjuvant
- MeSH:
Benzamides;
Female;
Follow-Up Studies;
Gastrectomy;
Gastrointestinal Stromal Tumors;
Humans;
Imatinib Mesylate;
Mesylates;
Microscopy;
Middle Aged;
Neoplasm, Residual;
Pancreas;
Piperazines;
Pyrimidines;
Spleen;
Splenectomy;
Stomach
- From:Journal of the Korean Surgical Society
2012;82(2):120-124
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 53-year-old woman was diagnosed with gastrointestinal stromal tumor (GIST) of the stomach. Computed tomography (CT) revealed a huge mass (12 cm in diameter), likely to invade pancreas and spleen. In the operation field, the tumor was in an unresectable state. The patient was then started on imatinib therapy for 4 months. On follow-up imaging studies, the tumor almost disappeared. We performed total gastrectomy and splenectomy upon which two small-sized residual tumors were found on microscopy. In this paper, we describe a case of clinicopathologic change in unresectable GIST after neoadjuvant imatinib mesylate.
